Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.